carboplatin


Also found in: Medical, Acronyms, Wikipedia.

carboplatin

[¦kär·bō′plat·ən]
(medicine)
A platinum coordination compound and anticancer agent used for advanced gynecologic malignancies, especially ovarian tumors, and for head and neck cancers and lung cancers.
References in periodicals archive ?
The company said the US FDA has approved the additional indication for ALIMTA (pemetrexed for injection) plus carboplatin and KEYTRUDA (pembrolizumab) for initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
IMpower133 is a Phase III, multicenter, double-blinded, randomized placebo- controlled study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin and etoposide) alone in chemotherapy-naive people with ES-SCLC.
The overall response rate for the carboplatin regimen was 75.9%, with 36.1% complete responses.
Placebo and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for four cycles and paclitaxel 200 mg/m2 on Day 1 of each 21-day cycle for four cycles or nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 21-day cycle for four cycles, followed by placebo every 3 weeks.
The triplet combination of ALIMTA and carboplatin with pembrolizumab (n=60) demonstrated a statistically significant improvement in objective response rate (ORR) versus ALIMTA plus carboplatin alone (n=63) (55% vs 29%; all responses were partial) (estimated difference, 26%; 95% confidence interval CI , range of 42-68 for triplet and range of 18-41 for ALIMTA plus carboplatin; P=0.0032), and PFS (HR=0.53; 95% CI, 0.31-0.91, P=0.0205).
The study, supported by the US National Cancer Institute (NCI), will evaluate the efficacy and safety of the combination of belinostat and carboplatin, or BelCar, in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or peritoneal cancer.
Sandra Horning, MD, Roche's chief medical officer and head of Global Product Development, said: "Our phase III results showed TECENTRIQ in combination with Avastin, paclitaxel and carboplatin has the potential to provide a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer.
Roche announced positive results from the Phase III IMpower150 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naive people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Eli Lilly (LLY) announced that the FDA has granted approval for a new indication for Alimta in combination with carboplatin and Keytruda for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, or NSCLC, irrespective of PD-L1 expression status.
Roche announced that the US Food and Drug Administration (FDA) has accepted the companys supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ (atezolizumab), in combination with Avastin (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Switzerland-based Roche has indicated a clinically significant survival benefit in a phase III lung cancer study of its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy), it was reported on Monday.
M2 PHARMA-November 2, 2018-FDA Approves US Merck's Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)